GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (FRA:1E6) » Definitions » Cyclically Adjusted Book per Share

Eagle Pharmaceuticals (FRA:1E6) Cyclically Adjusted Book per Share : €11.35 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Eagle Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2023 was €17.765. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.35 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Eagle Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-12), Eagle Pharmaceuticals's current stock price is €3.24. Eagle Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was €11.35. Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.29.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Eagle Pharmaceuticals was 4.40. The lowest was 0.28. And the median was 1.60.


Eagle Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Eagle Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Cyclically Adjusted Book per Share Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 10.70

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.03 12.96 10.70 10.87 11.35

Competitive Comparison of Eagle Pharmaceuticals's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Eagle Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eagle Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book= Book Value per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=17.765/128.7287*128.7287
=17.765

Current CPI (Jun. 2023) = 128.7287.

Eagle Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 -4.725 98.790 -6.157
201312 0.041 98.326 0.054
201403 2.304 99.695 2.975
201406 2.200 100.560 2.816
201409 1.830 100.428 2.346
201412 1.612 99.070 2.095
201503 6.130 99.621 7.921
201506 5.512 100.684 7.047
201509 5.008 100.392 6.422
201512 5.304 99.792 6.842
201603 5.302 100.470 6.793
201606 6.138 101.688 7.770
201609 6.091 101.861 7.698
201612 9.355 101.863 11.822
201703 10.227 102.862 12.799
201706 9.702 103.349 12.085
201709 9.620 104.136 11.892
201712 10.195 104.011 12.618
201803 9.763 105.290 11.936
201806 10.568 106.317 12.796
201809 11.147 106.507 13.473
201812 10.156 105.998 12.334
201903 11.141 107.251 13.372
201906 11.169 108.070 13.304
201909 11.675 108.329 13.873
201912 11.831 108.420 14.047
202003 12.043 108.902 14.236
202006 12.008 108.767 14.212
202009 11.258 109.815 13.197
202012 11.710 109.897 13.717
202103 12.210 111.754 14.065
202106 12.348 114.631 13.867
202109 12.167 115.734 13.533
202112 12.208 117.630 13.360
202203 15.444 121.301 16.390
202206 16.965 125.017 17.469
202209 17.986 125.227 18.489
202212 16.938 125.222 17.412
202303 17.335 127.348 17.523
202306 17.765 128.729 17.765

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Eagle Pharmaceuticals  (FRA:1E6) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eagle Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.24/11.35
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Eagle Pharmaceuticals was 4.40. The lowest was 0.28. And the median was 1.60.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Eagle Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (FRA:1E6) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals (FRA:1E6) Headlines

No Headlines